This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting, held in Lisbon in June 2017, which brought together national experts from the 28 EU Member States, Norway, Turkey, European neighbourhood countries and partner organisations.
This paper gives an overview of some recent developments in the tools most commonly used to manage national drug policies: strategies, coordination mechanisms and evaluations. It is based on an analysis of reports on national drug policies compiled by the EMCDDA’s Reitox focal points in the EMCDDA reporting countries (28 EU Member States, plus Turkey and Norway), consultation with experts and scientific literature.
The Commissioner will meet EMCDDA Director Alexis Goosdeel and the agency’s experts in the area of security.
A Trendspotter study is a rapid information assessment that uses multiple social research methods to explore a topic of interest or concern. The approach was developed and has been used by
the EMCDDA since 2011 as a tool to complement other routine drug monitoring methodologies.
Drug markets can be seen from the perspective of supply and demand. Market-related indicators, therefore, particularly administrative data, such as seizures, price, purity and drug-related offences, are used in most countries for assessment of the drug situation and policy evaluation. However, the illicit nature of drug markets limits data availability and interpretation.
For more than 20 years, the European information network on drugs and drug addiction (Reitox), has been the cornerstone of the European drug monitoring and reporting system, to which it
contributes by collecting, analysing, interpreting and disseminating data at national level, as well as by defining the tools for monitoring. Reitox is a partner and an integral part of the EMCDDA, a key player at EU and international level. The Reitox network currently includes the 28 EU Member States plus Turkey, Norway and the European Commission.
The problem drug use (PDU) indicator is one of the five EMCDDA key epidemiological indicators, addressing key aspects of the prevalence and harms of drug use at the European level. National
experts from the PDU network provide prevalence estimates of high-risk drug use by substance and the prevalence of people who inject drugs (PWID).
Knowledge of the extent and patterns of drug use in the general population, and their changes over time, is essential to understanding the drug phenomenon in Europe and to monitoring progress towards EU and national policy targets. The primary purpose of the prevalence and patterns of drug use in the general population (GPS) indicator is to allow the estimation of the prevalence of drug use.
Injecting drugs is a key risk factor for contracting viral and other infections. Blood-borne infections acquired through the sharing of injecting equipment are among the most serious health harms of drug use. The drug-related infectious disease (DRID) indicator collects data on the extent of such infections, primarily human immunodeficiency virus (HIV) and hepatitis B and C viruses (HBV and HCV), among people who inject drugs (PWID).
Comparable and reliable data about the number and characteristics of people entering specialised drug treatment in EU Member States is essential for understanding the European drug problem. The primary purpose of the treatment demand indicator (TDI) is to gain insight into the socio-demographic profile and illicit drug use patterns of those entering drug treatment.
High-risk drug use is one of the major causes of avoidable mortality in Europe, both directly through overdose and indirectly through drug-related diseases, accidents, violence and suicide. The primary purpose of the drug-related deaths indicator is to improve the understanding of the health impact of different forms of drug use and its correlates and determinants, in order to inform the development and evaluation of policies and interventions.
This guide and the associated package of online materials provides a reference point for planning or delivering health and social responses to drug problems in Europe. The most appropriate responses will depend on the specific drug problems, the contexts in which these occur and the types of intervention that are possible and socially acceptable. By providing key information on some of the most important drug issues for Europe and the responses available, this guide aims to assist those involved in tackling these challenges to develop new programmes and improve existing ones.
Today the EMCDDA launches Xchange, a new online registry of evidence-based prevention programmes. In its first phase, the registry will make available manualised interventions that European evaluation studies show to have beneficial outcomes relating to substance use.
Tthe agency’s first overview of actions and interventions currently available to address the consequences of illicit drug use was launched today.
Leading international experts in the field of addiction science will meet in Lisbon from 24–26 October 2017.
It is estimated that over 1 million people receive treatment for drug-related problems in the European Union every year. With shrinking public budgets, increasing pressure on health systems, changes in the drugs used and the need to provide on-going care to chronic cases, what is the real cost of drug treatment in Europe? In collaboration with experts from around the globe, the EMCDDA has compiled this analytical report, the first of its kind, to present the current practices used for estimating drug treatment costs in order to help fill the knowledge gap.
The international conference on wastewater analysis, organised by the SCORE group and the EMCDDA will take place on 26–27 October.
How can we estimate the cost of drug treatment in Europe? This is the question explored in a new EMCDDA report.
The 3rd International symposium on drug-impaired driving will be held on 23 October in Lisbon.
The acclaimed writers will receive a non-monetary prize and present their articles during the Lisbon Addictions conference.
Evaluation is essential for effective policymaking, helping ensure that policies and programmes have the desired effect, provide value for money and do not have negative unintended consequences. The importance of evaluation has been recognised in all EU drug strategies and in the strategies of many Member States.
To support those considering or involved in commissioning, managing or undertaking policy evaluations, this page provides access to a range of materials, including a 7-step guide, examples of strategies and evaluations in Europe and potentially useful data sources.
This document summarises the main issues concerning evaluation in the field of drug policy. Aimed at those managing rather than undertaking drug policy evaluations, the guide acts as an introduction, providing links to the wider literature. Recognising that there is no single correct way to undertake an evaluation, this publication is designed to assist people in choosing the best approach to suit their circumstances and to maximise the value of any evaluation.
Today, the EMCDDA launches a new package of online resources designed to inform and support those considering, or involved in, drug policy evaluation.
This week, the EU has reacted to serious concerns over the use of the synthetic opioid acryloylfentanyl by deciding to subject it to ‘control measures’ throughout the Union.
Health and social responses to drug problems in Europe will be placed in the spotlight in a pioneering new EMCDDA guide to be launched on 24 October during Lisbon Addictions 2017.
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran- 2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3- carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.